Unicycive Therapeutics, Inc. (UNCY) News
Follow Unicycive Therapeutics, Inc. (UNCY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 25 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
FDA Accepts Unicycive Therapeutics’ Resubmitted NDA
The FDA accepted the company’s resubmitted New Drug Application for oxylanthanum carbonate. Unicycive shares rose 5% to $4 in morning trade.
REGULATION | Oct 21, 2026, 02:22 PM UTC
M
FDA Accepts Unicycive’s Oxylanthanum Carbonate NDA Resubmission
Unicycive Therapeutics said the FDA accepted its resubmitted new drug application for oxylanthanum carbonate and set a PDUFA date of March 25, 2027.
REGULATION | Oct 21, 2026, 11:07 AM UTC
L
Unicycive Therapeutics Price Target Cut to $13.00/Share From $15.00 by HC Wainwright & Co.
Ratings actions from Benzinga: GMT) Unicycive Therapeutics Is Maintained at Buy by HC Wainwright & Co.Ratings actions from Benzinga
NEWS | Sep 29, 2026, 03:49 PM UTC
L
HC Wainwright & Co. maintains Buy rating on Unicycive Therapeutics, $13 price target
HC Wainwright & Co. maintained their Buy rating on Unicycive Therapeutics's stock with a price target of $13.00.The price target implies an upside of 180.2% from the Sep 28 close of $4.64.Key takeaways from the analyst n
EQUITY | Sep 29, 2026, 03:39 PM UTC
L
Unicycive appoints Meredith S. Manning to its board as Nominating Committee Chair
Unicycive appointed Meredith S. Manning as an independent director and named her Chairperson of the Nominating and Corporate Governance Committee, effective October 1, 2026.Original SEC Filing: Unicycive Therapeutics, In
REGULATION | Sep 29, 2026, 11:53 AM UTC
L
Unicycive Therapeutics, Inc. (UNCY) Resubmits NDA for Oxylanthanum Carbonate
Unicycive resubmitted its NDA for oxylanthanum carbonate, expecting FDA acceptance within 30 days and a six—month review clock. The resubmission uses a new CMC vendor with an FDA “No Action Indicated” 2024 inspection.Mat
REGULATION | Sep 29, 2026, 11:09 AM UTC
L
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
MOUNTAIN VIEW, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) NASDAQ:UNCY, a clinical-stage biotechnology company developing therapies for patients with kidney dise
NEWS | Sep 29, 2026, 11:08 AM UTC
L
Unicycive Therapeutics faces securities class action tied to NDA statements
Unicycive Therapeutics reported a securities class action filed alleging misleading statements about its oxylanthanum carbonate NDA; the company says it will defend the suit.Key Highlights:Original SEC Filing: Unicycive
REGULATION | Sep 28, 2026, 08:36 PM UTC
L
Unicycive Therapeutics CEO to present at H.C. Wainwright conference
Unicycive Therapeutics said Shalabh Gupta, M.D., the company’s CEO, will present at the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 01, 2026, 11:07 AM UTC
L
Unicycive Therapeutics to present at H.C. Wainwright conference
Unicycive Therapeutics (UNCY) will present at the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 01, 2026, 11:05 AM UTC
L
Unicycive Therapeutics Posts Q2 2026 Results
Unicycive Therapeutics announces second quarter 2026 financial results
EARNINGS | Aug 12, 2026, 11:19 AM UTC
H
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings
Prediction market platform Kalshi is expanding into biotech, launching contracts Wednesday night that let traders bet on clinical trial outcomes and drug approvals from companies including Sanofi (NASDAQ: SNY ) and Gilea
REGULATION | Jul 16, 2026, 05:29 PM UTC
L
Unicycive Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
Boston, Massachusetts--(. - July 6, 2026) - Block & Leviton is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) for potential securities law violations. Investors who have lost mo
EQUITY | Jul 06, 2026, 12:43 PM UTC
L
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ: UNCY ) with a Speculative Buy and lowers the price target from $18 to $13.
EQUITY | Jul 01, 2026, 03:33 PM UTC
L
Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50
Noble Capital Markets analyst Robert LeBoyer maintains Unicycive Therapeutics (NASDAQ: UNCY ) with a Outperform and lowers the price target from $60 to $50.
EQUITY | Jul 01, 2026, 01:51 PM UTC
L
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Alzamend Neuro (NASDAQ: ALZN ) stock increased by 12.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $4.4 million. Vivos Therapeutics (NASDAQ: VVOS ) shares increased by 9.92
GEOPOLITICS | Jun 30, 2026, 09:05 PM UTC
L
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $15
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ: UNCY ) with a Buy and lowers the price target from $22 to $15.
EQUITY | Jun 30, 2026, 05:29 PM UTC
L
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Creative Medical Tech (NASDAQ: CELZ ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings (Cayman) (NASDAQ: C
EQUITY | Jun 30, 2026, 05:05 PM UTC
L
B. Riley Securities Maintains Buy on Unicycive Therapeutics, Maintains $22 Price Target
B. Riley Securities analyst Mayank Mamtani maintains Unicycive Therapeutics (NASDAQ: UNCY ) with a Buy and maintains $22 price target.
EQUITY | Jun 30, 2026, 05:01 PM UTC
L
Nasdaq Gains Over 300 Points; Chicago PMI Falls In June
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 300 points on Tuesday. The Dow traded up 0.28% to 52,327.93 while the NASDAQ rose 1.31% to 26,157.23. The S&P 500 also rose, gainin
MACRO | Jun 30, 2026, 04:08 PM UTC
L
Why Is Unicycive Therapeutics Stock Falling Tuesday?
Unicycive Therapeutics, Inc. (NASDAQ: UNCY ) on Monday said the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for its resubmitted New Drug Application (NDA) seeking approval of oxylanthanu
GEOPOLITICS | Jun 30, 2026, 03:04 PM UTC
L
US Stocks Mixed; Home Prices Increase 1.1% In April
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 0.2% on Tuesday. Following the market opening Tuesday, the Dow traded down 0.18% to 52,091.03 while the NASDAQ rose 0.36% to 25,912.25. The S
RATES | Jun 30, 2026, 01:47 PM UTC
H
Select Premarket Movers
Upside: -AVAV +35% (earnings, guidance) -VWAV +29% (acquires 51% controlling interest in private Israeli aerospace and defense company Meteor Aerospace for ~$20.4M in stock) -SEDG +11% (solar stock strength following FCC
GEOPOLITICS | Jun 30, 2026, 12:26 PM UTC
L
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Abivax (NASDAQ: ABVX ) shares increased by 36.0% to $130.74 during Tuesday's pre-market session. The company's market cap stands at $7.6 billion. Cuprina Holdings (Cayman) (NASDAQ: CUPR ) shares moved upwards by
EQUITY | Jun 30, 2026, 12:05 PM UTC
M
Unicycive Therapeutics Receives FDA Complete Response Letter On Its Application For Oxylanthanum Carbonate For Hyperphosphatemia In Patients
Unicycive Therapeutics, Inc. (NASDAQ: UNCY ), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it has received a Complete Response Letter (CRL) from the U
REGULATION | Jun 30, 2026, 11:10 AM UTC